> The FDA has granted fast track status to Accentia Biopharmaceuticals' drug for non-Hodgkins lymphoma. Report
> Shares of Barr Pharmaceutical dropped after the patent office rejected its attempt to get a patent reissued for Seasonale. Report
> Medical experts expect the FDA to approve Merck's vaccine against cervical cancer. Article
> Novartis is expected to make waves next at next week's meeting of the American Society of Hypertension with news about its experimental blood pressure drugs. One of those drugs is Rasilez, which was developed with Speedel. Article
> A new study indicates that Novartis' Glivec could inhibit bone formation. Report
> Sweden's Biacore International has launched a sales and marketing operation in China. Report
> Neurologix has raised $12 million in a private placement. Report
> Chutes & Ladders: Celldex Therapeutics has named Robert Forbes Burns as CEO. Report
> India and Pakistan are exploring setting up joint clinical trials for pharmaceuticals. Report
> Israel's Neuroderm has received $490,000 in funding by The Michael J. Fox Foundation for Parkinson's Research. Release
And Finally… With plans being developed for responding to an avian flu pandemic, ethicists are wondering if limited supplies of vaccine should be reserved for first responders or the young people who are most at risk and have the most to lose. Article